Independent Director Kathryn Falberg Just Bought 12% More Shares In Arcus Biosciences, Inc. (NYSE:RCUS)
Arcus Biosciences, Inc. (NYSE:RCUS) shareholders (or potential shareholders) will be happy to see that the Independent Director, Kathryn Falberg, recently bought a whopping US$567k worth of stock, at a price of US$28.35. Not only is that a big swing, but it increased their holding size by 12%, which is definitely great to see.
Check out our latest analysis for Arcus Biosciences
The Last 12 Months Of Insider Transactions At Arcus Biosciences
In the last twelve months, the biggest single purchase by an insider was when Co-Founder Terry Rosen bought US$999k worth of shares at a price of US$23.38 per share. So it's clear an insider wanted to buy, at around the current price, which is US$28.83. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. In this case we're pleased to report that the insider purchases were made at close to current prices.
Happily, we note that in the last year insiders paid US$1.7m for 68.91k shares. But they sold 12.91k shares for US$444k. In total, Arcus Biosciences insiders bought more than they sold over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership of Arcus Biosciences
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Arcus Biosciences insiders own 8.7% of the company, worth about US$178m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About Arcus Biosciences Insiders?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Arcus Biosciences. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Arcus Biosciences. Our analysis shows 5 warning signs for Arcus Biosciences (2 are concerning!) and we strongly recommend you look at them before investing.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
